Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
Manfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Haematologica
|
September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
Dennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
The Lancet. Oncology
|
March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Nature Communications
|
March 4, 2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Maurizio Callari, Matteo Dugo, Marco Barreca, et al.
The New England Journal of Medicine
|
July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
Simonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
Frontiers in Oncology
|
February 28, 2022
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, et al.
JAMA Oncology
|
January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
Luca Gianni, Mauro Mansutti, Antonio Anton, et al.
The Lancet. Oncology
|
May 16, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
The Lancet. Oncology
|
December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Molecular Oncology
|
November 24, 2021
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
Manfred Kaufmann, Gabriel N Hortobagyi, Aron Goldhirsch, et al.
Haematologica
|
September 16, 2017
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
Dennis A Eichenauer, Ingrid Becker, Ina Monsef, et al.
The Lancet. Oncology
|
March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Nature Communications
|
March 4, 2025
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Maurizio Callari, Matteo Dugo, Marco Barreca, et al.
The New England Journal of Medicine
|
July 22, 2011
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned
Simonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi, et al.
Frontiers in Oncology
|
February 28, 2022
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, et al.
JAMA Oncology
|
January 13, 2018
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
Luca Gianni, Mauro Mansutti, Antonio Anton, et al.
The Lancet. Oncology
|
May 16, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
The Lancet. Oncology
|
December 14, 2011
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, et al.
Molecular Oncology
|
November 24, 2021
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, et al.
Page
of 6